Table 1
2009201020112012201320142015p-value
N10490162999010862
Age (years), mean (SD)42.3 (11.2)40.5 (11.8)42.5 (12.6)40.3 (11.1)42.1 (12.8)42.9 (11.6)42.8 (12.4)0.59
Proportion female33.0%36.0%47.8%38.4%40.0%37.0%38.7%0.29
Years since diagnosis, median (IQR)4.5 (0.8, 14.5)4.6 (0.7, 15.4)5.4 (0.7, 16.0)3.3 (0.6, 13.6)1.3 (0.4, 8.5)1.9 (0.2, 7.0)2.5 (0.2, 10.8)0.088
Disease Activity Score 28 joints, mean (SD)3.04 (1.18)3.09 (1.06)2.97 (1.04)2.76 (1.06)2.78 (0.91)2.79 (0.94)2.60 (0.81)0.051
Clinical Disease Activity Index, mean (SD)11.02 (5.54)11.43 (6.92)10.20 (4.87)10.08 (4.99)9.41 (2.83)10.42 (5.41)9.08 (4.28)0.15
Simplified Disease Activity Index, mean (SD)12.52 (6.11)12.90 (7.21)11.34 (5.45)10.43 (5.27)10.45 (3.14)11.41 (5.97)9.63 (4.49)0.015
Adalimumab91.3%33.3%22.2%15.2%18.9%13.0%0.0%<0.001
Certolizumab0.0%2.2%0.0%0.0%11.1%74.1%43.5%
Etanercept7.7%7.8%61.7%67.7%5.6%2.8%3.2%
Golimumab0.0%55.6%12.3%12.1%63.3%3.7%4.8%
Infliximab1.0%1.1%3.7%5.1%1.1%0.0%0.0%
Infliximab biosimilar0.0%0.0%0.0%0.0%0.0%6.5%48.4%
  • p-values for between-year differences.